TABLE 3.
Susceptiblities of PCV-selected HSV-2 in MRC-5 cells
| SB5 isolateb | IC50 (μg/ml)a
|
|||||
|---|---|---|---|---|---|---|
| ACV (0.5) | PCV (0.75) | BVDU (8.1) | FOS (35.0) | Ara-A (1.8) | CDU (0.7) | |
| 2P1 | 80.6 | >100 | 21.2 | 14.4 | 6.5 | 0.5 |
| 2P2 | >100 | >100 | >50 | 40.5 | 2.0 | 0.9 |
| 2P3-A | 0.11 | 0.4 | 4.0 | 25.0 | 2.0 | 0.7 |
| 2P3-B | 0.11 | 0.4 | 4.5 | 18.5 | 2.1 | 0.5 |
| 2P4 | 67.0 | >100 | 26.1 | 21.2 | 0.9 | 1.8 |
| 2P5 | 26.0 | 63.0 | 18.2 | 24.5 | 2.6 | 2.9 |
| 2P6 | 60.0 | 45.0 | >10.0 | 40.5 | 2.5 | 0.5 |
| 2P7 | 50.0 | >100 | >10.0 | 10 | 1.0 | 0.3 |
| 2P8 | >100 | 68.4 | >50 | 48.2 | 4.3 | 2.2 |
| 2P9 | 29.8 | >100 | 45.0 | 32.3 | 2.8 | 3.0 |
| 2P10 | >100 | 60.7 | >10.0 | >400 | 7.8 | 0.5 |
a
Susceptibility data for wild-type HSV-2 SB5 are from the initial virus preparation used for these studies and are listed in parentheses.
b
Each plaque isolate was purified from a unique starting well, except 2P3-A and 2P3-B, which are separate plaque isolates purified from the same well.